Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer

KE XU¹, BIN LIU² and YONGYU LIU¹

Departments of ¹Thoracic Surgery and ²Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China

Received July 30, 2014; Accepted January 23, 2015

DOI: 10.3892/mmr.2015.3348

Abstract. The objective of the current study was to investigate the impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer (NSCLC). In 115 archived NSCLC tissue samples, the expression of Brachyury was observed to be significantly higher than that in adjacent normal lung tissues. In addition, the current study demonstrated that the expression of Brachyury is closely associated with TNM staging, lymph node metastasis and the prognosis of NSCLC, although not with patient age, gender or tumor differentiation. Brachyury expression is also accompanied by the downregulation of E-cadherin and the upregulation of N-cadherin. Brachyury may promote lung cancer through induction of epithelial-mesenchymal transition, which leads to metastasis and consequent poor prognosis in patients with lung cancer. Furthermore, the present study observed that interfering with Brachyury increases the sensitivity of cells to chemotherapeutic treatment with cisplatin. These results, in combination with those of additional studies, suggest that Brachyury may be used as a novel target for the prevention and treatment of lung cancer.

Introduction

Epithelial-mesenchymal transition (EMT) was initially described by developmental biologists, who indicated specific morphological and phenotypic alterations in epithelial cells during embryonic development (1). During this process, epithelial cells lose their polarity and become similar in morphology to fibroblasts, with reduced adhesion to the surrounding cells and matrix, thus acquiring an enhanced migratory ability (2).

It is currently hypothesized that EMT is accompanied by alterations in the expression of specific epithelial and mesenchymal markers. Epithelial cell markers such as E-cadherin, desmoplakin, tight junction protein, keratin, α-catenin, β-catenin and γ-catenin are downregulated in EMT, whereas the expression of mesenchymal tissue markers such as N-cadherin, α-smooth muscle actin, vimentin and fibronectin protein is increased (3). Furthermore, other EMT-related proteases, cytokines and transcription factors, including matrix metalloproteinase-2/9, transforming growth factor, fibroblast growth factor, Snail, Slug and Twist, are also upregulated (4). In addition to its role in embryonic development, previous studies have indicated that EMT is closely associated with tumor progression and resistance to chemotherapy (5). This has resulted in an increased focus on EMT by academics, clinicians and pharmaceutical researchers.

A large body of evidence indicates that the transcription factor Brachyury, which is a member of the T-box family, serves a key function during the process of EMT (5-7). T-box family members contain the highly-conserved DNA-binding domain, known as the T-box domain (8). As is the case with the other family members, Brachyury is among the proteins that are conserved during the differentiation process of the mesoderm (9-12). Previous studies have suggested that Brachyury is vital in the formation of the notochord (9). In vitro experiments have also indicated that Brachyury may induce mesenchymal differentiation in the embryonic stem cells of the rhesus monkey (9,11,12). A previous study demonstrated high expression levels of Brachyury in a number of types of human cancer (13), which suggests that Brachyury is important in the process of tumorigenesis, and may therefore be a novel therapeutic target in human cancer.

In the current study, the expression levels of Brachyury in normal human lung tissues and in tumor samples from patients with non-small cell lung cancer (NSCLC) were examined. The associations between Brachyury and various clinicopathological factors were analyzed in 115 NSCLC samples. The impact of Brachyury on the proliferative and invasive capacities of lung cancer cells, in addition to NSCLC cell chemosensitivity, was also investigated.

It was hypothesized that Brachyury is involved in the induction of EMT, and that via this induction, upregulation of Brachyury in NSCLC is able to exacerbate tumor malignancy.
Materials and methods

Patients and specimens. Ethical approval for the current study was obtained from the Ethics committee of the Liaoning Cancer Hospital and Institute (Shenyang, China). Primary tumor specimens were obtained from 115 patients diagnosed with NSCLC, who underwent complete tumor resection in the Liaoning Cancer Hospital and Institute between January and December 2007. Control samples were taken from adjacent non-cancerous normal lung tissues of the same patients. Written informed consent was obtained from each patient or their family. All 115 patients had complete follow-up records and received no radiotherapy or chemotherapy prior to surgery. The 115 patients with NSCLC comprised 80 males and 35 females, with a median age of 67.3 years (range, 47-86 years). The pathological TNM (pTNM) staging system of the Union for International Cancer Control (seventh edition) (14) was used to classify specimens as: Stage I (n=40), stage II (n=33) and stage III-IV (n=42). According to the classification of lung cancer by the World Health Organization classification guidelines, 70 cases were categorized as squamous cell carcinoma and 45 cases as adenocarcinoma.

Immunohistochemistry. Surgically excised specimens were fixed with 10% neutral formalin (Fuzhou Maixin Biotechnology Development Co., Fuzhou, China), embedded in paraffin (Leica, Wetzlar, Germany), and cut into 4-µm sections. Immunostaining was conducted using the avidin-biotin-peroxidase complex method (Ultrasensitive™; Fuzhou Maixin Biotechnology Development Co.). The expression levels of Brachury, E-cadherin and N-cadherin were measured in 115 NSCLC specimens, using the corresponding antibodies (goat anti-human polyclonal anti-Brachury, 1:100; sc-17745; mouse anti-human monoclonal anti-E-cadherin, 1:100, sc-8426; and goat anti-human polyclonal anti-N-cadherin, 1:100, sc-31030; all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and the membranes were incubated overnight at 4˚C with goat anti-human polyclonal anti-Brachury (1:100; sc-17745; Santa Cruz Biotechnology). After incubation with peroxidase-coupled anti-goat immunoglobulins (Santa Cruz Biotechnology) at 37˚C for 2 h, bound proteins were visualized by electrochemiluminescence (Pierce) and detected by BioImaging System (UV, Upland, CA, USA).

Matrigel invasion assay. The bottom of the Transwell® chambers (Costar, Cambridge, MA, USA) was covered with Matrigel® (BD Biosciences, San Jose, CA, USA), 1:8, diluted in RPMI 1640 medium (~50 µg/chamber). For sterilization, the prepared chambers were irradiated with ultraviolet rays for 2 h. Prior to use, a small amount of serum-free medium (Invitrogen Life Technologies) was added, in order to hydrate the chambers. A total of 0.5 ml RPMI 1640 medium containing 1% FBS was added to the lower chamber, 1.5x10⁶/ml cells were added to the upper chamber and the chambers were subsequently incubated at 37˚C for 48 h. The small chamber was removed and rinsed with PBS and the cells from the upper chamber were then removed from the microporous membrane using a cotton swab. Cells were then fixed in 95% ethanol and stained with 0.5% methylene blue (Sigma-Aldrich). The microporous membranes of the lower chamber of cells was counted under an inverted microscope (x200; TE2000; Nikon, Tokyo, Japan).

Cell culture and transfection. The A549 human lung adenocarcinoma cell line was purchased from the American Type Culture Collection (Manassas, VA, USA) cultured in RPMI 1640 medium (Invitrogen Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Invitrogen Life Technologies). Small interfering RNAs (siRNAs) for Brachury, in addition to non-targeting siRNA, were purchased from Santa Cruz Biotechnology, Inc., and consisted of pools of three to five siRNAs to avoid off-target effects. Brachury siRNA was transfected into the A549 cell line using Lipofectamine® 2000 (Invitrogen Life Technologies).

MTT assay. Cells were plated in four 96-well plates in RPMI 1640 medium containing 10% FBS at a density of 1x10⁵/ml cells per well. Each plate was divided into three groups: Blank, control siRNA and Brachury siRNA. For quantification of cell viability, 20 µl 5 mg/ml MTT (Sigma-Aldrich, St. Louis, MO, USA) was added to each well at 24, 48, 72 and 96 h post-transfection. Following 4 h incubation, the media was removed from each well and the resultant MTT formazan was solubilized in 150 µl dimethyl sulfoxide (Sigma-Aldrich). The results were quantitated spectrophotometrically (Bio-Rad 550; Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a wavelength of 490 nm. The experiments were repeated three times and growth curves of the cells were plotted accordingly.

Western blot analysis. Total proteins from cells were extracted in lysis buffer (Pierce, Rockford, IL, USA) and quantified using the Bradford method. Fifty micrograms of protein was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis. Separated proteins were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), and the membranes were incubated overnight at 4˚C with goat anti-human polyclonal anti-Brachury (1:100; sc-17745; Santa Cruz Biotechnology). After incubation with peroxidase-coupled anti-goat immunoglobulins (Santa Cruz Biotechnology) at 37˚C for 2 h, bound proteins were visualized by electrochemiluminescence (Pierce) and detected by BioImaging System (UV, Upland, CA, USA).

DDP toxicity analysis. A549 cells (3x10⁵ cells/well) were cultured in a 96-well plate for 18 h. Each plate was divided into three groups: Blank, control siRNA and Brachury siRNA, according to transfection treatment. After 48 h, 1, 3 or 5 µg/ml cisplatin (DDP) was added to the culture medium of each group and incubated for 24 h. The control siRNA group with DDP treatments formed the DDP treatment groups; the Brachury siRNA group with DDP treatments formed the combination treatment groups. The endpoint viability of the A549 cells was quantified at 24 h following DDP treatment.
Table I. Summary of the correlation between Brachyury expression and clinicopathological characteristics of NSCLC.

| Characteristic                  | n  | Negative | Positive | $\chi^2$ | P-value |
|--------------------------------|----|----------|----------|----------|---------|
| Age (years)                    |    |          |          |          |         |
| <63                            | 46 | 28       | 18       | 0.096    | 0.757   |
| ≥63                            | 69 | 40       | 29       |          |         |
| Gender                         |    |          |          |          |         |
| Male                           | 80 | 52       | 28       | 3.747    | 0.053   |
| Female                         | 35 | 16       | 19       |          |         |
| Histology                      |    |          |          |          |         |
| Squamous cell carcinoma        | 70 | 48       | 22       | 6.6      | 0.01*   |
| Adenocarcinoma                 | 45 | 20       | 25       |          |         |
| Tumor differentiation          |    |          |          |          |         |
| Well to moderate               | 93 | 54       | 39       | 0.229    | 0.633   |
| Low                            | 22 | 14       | 8        |          |         |
| TNM stage                      |    |          |          |          |         |
| I+II                           | 73 | 50       | 23       | 7.25     | 0.007*  |
| III+IV                         | 42 | 18       | 24       |          |         |
| Lymph node metastasis          |    |          |          |          |         |
| Yes                            | 61 | 46       | 15       | 14.25    | <0.001* |
| No                             | 54 | 22       | 32       |          |         |

*P<0.05, indicate statistical significance. NSCLC, non-small cell lung cancer; n, number.

Figure 1. Immunostaining demonstrating the expression of Brachyury in non-small cell lung cancer tissues and matched adjacent non-cancerous lung tissues. Brachyury was negatively or weakly expressed in the cytoplasm of the matched adjacent non-cancerous normal lung tissue (A) and (B). In the lung cancer cells (C) and (D), Brachyury was predominantly located in the nucleus, with only a low level of cytoplasmic expression (magnification, x200; red bar, 50 µm).
using the MTT assay, as described above. The effect of DDP alone or in combination with Brachyury-specific siRNA on the cell proliferation inhibition rate after 24 h was calculated as follows: Cell proliferation inhibition rate (%) = (1 - the OD_{570} value of the experimental group/the OD_{570} value of the control group) x 100. The experiment was repeated three times.

**Statistical analysis.** SPSS version 13.0 for Windows was used for all statistical analyses (SPSS, Inc., Chicago, IL, USA). The Pearson $\chi^2$ test was used to examine possible correlations between Brachyury and clinicopathological factors of NSCLC. The Kaplan-Meier method was used to evaluate the prognosis of patients. $P<0.05$ was considered to indicate a statistically significant difference.

**Results**

**Clinical significance of Brachyury expression in NSCLC.** Brachyury was observed to be negatively or weakly expressed in the cytoplasm of the matched normal lung tissues, adjacent to the cancer tissues, and was defined as negative expression according to the rating criteria (Fig. 1A and B). In the lung cancer tissues, Brachyury was predominantly located in the...
nucleus, with a low level of cytoplasmic expression. The proportion of cells that was positive for Brachyury expression was 40.87% (47/115), which was significantly higher than that in the normal lung tissues (0/115; P<0.001) (Fig. 1C and D).

Associations between Brachyury expression and clinicopathological factors are presented in Table I. The positive expression of Brachyury in lung adenocarcinoma was 55.56% (25/45), which was significantly higher than that in squamous cell carcinoma samples (31.43%, 22/70; P=0.01). The positive expression of Brachyury was also correlated with higher tumor stages (III+IV vs. I+II; P<0.001) and lymph node metastases (P<0.001). However, no correlation was observed between Brachyury expression and patient age, gender or tumor differentiation (P>0.05, Table I).

Kaplan-Meier survival analysis showed that patients with Brachyury expression exhibited shorter average survival times compared with patients with negative expression of Brachyury (34.21±3.01 vs. 45.81±2.37 months; P=0.001). This suggested that Brachyury expression is associated with a poorer prognosis (Fig. 2).

The impact of Brachyury on the expression of N-cadherin and E-cadherin in lung cancer. Immunohistochemical analysis demonstrated a high expression of E-cadherin in the
Brachyury-negative lung cancer tissues, with obvious staining of the cell membrane (Fig. 3A and B), whereas N-cadherin expression was either negative or low (Fig. 3C). By contrast, in the Brachyury-positive lung cancer tissues, E-cadherin expression was significantly reduced (Fig. 3D and E), while N-cadherin expression was increased, with marked membrane staining (Fig. 3F).

**Brachyury promotes lung cancer cell proliferation and invasion.** In order to study the impact of Brachyury expression on cell proliferation, an MTT assay was used. In the A549 human lung adenocarcinoma cell line, 24 h following treatment with Brachyury-specific siRNA, no significant difference in the proliferative capacity of each group was observed (P>0.05; Fig. 4A and B). However, from the second day, the lung cancer cells treated with Brachyury-specific siRNA, demonstrated a lower proliferative capacity compared with the control group (Fig. 4B, P<0.05).

A Matrigel assay was performed to study the impact of Brachyury on the invasive capacity of A549 cells. The results indicated that 48 h after Brachyury knockdown, the average number of invasive cells was 19.17±2.89, which was significantly lower than that in the control group (63.47±2.93; P<0.05; Fig. 4C and D).

**Knockdown of Brachyury increases cell sensitivity to DDP.** DDP is a widely used chemotherapeutic drug and is frequently administered as combination chemotherapy (15). Therefore, the cell toxicity of DDP was tested in combination with silencing of Brachyury in A549 cells. In the MTT assay, the OD of cells in the control group without DDP treatment was 0.703±0.006. The OD of cells treated with 1, 3 or 5 µg/ml DDP was observed to be 0.598±0.014, 0.573±0.012 and 0.490±0.013, respectively. However, when combining DDP (1, 3 and 5 µg/ml) with Brachyury-specific siRNA, the OD of cells was 0.483±0.027, 0.436±0.012 and 0.334±0.018, respectively (Fig. 5A; P<0.01 between the DDP and combination groups at each corresponding concentration). This indicated that the combination of these treatment may result in a higher cytotoxicity in A549 cells than DDP treatment alone.

For cells treated with 1, 3 or 5 µg/ml DDP, the cell growth inhibition rates were 7.53±0.88%, 16.40±0.73% and 24.54±0.95%, respectively. When combining DDP with Brachyury-specific siRNA, the cell growth inhibitory rates were 24.79±0.64, 32.33±1.16 and 48.54±1.00%, respectively (Fig. 5B; P<0.01 between the DDP and combination groups at each corresponding concentration). Thus, with the same concentration of DDP, there was a higher cytotoxic effect for the combined treatment group than the DDP alone group.

**Discussion**

Brachyury is a T-box transcription factor, containing the highly conserved T-domain, which has the capacity to bind to DNA (5-7). Overexpression of Brachyury in human carcinoma cells is reported to induce alterations in the characteristics of EMT, including an increase in mesenchymal markers, a reduction of epithelial markers, and the upregulation of cell migration and invasion (16). However, the mechanisms underlying the involvement of Brachyury in EMT remain to be fully elucidated in human lung cancer. Therefore, the current study aimed to investigate the role of Brachyury in EMT and chemosensitivity in 115 NSCLC samples.

A previous study observed that Brachyury is highly expressed in various human tumor cell lines, but not in the majority of healthy human adult tissues (13). In accordance with this finding, the current study identified that Brachyury was negatively or weakly expressed in the cytoplasm of normal lung tissue samples, whereas it was predominantly positively expressed in the NSCLC tissues. The associations between Brachyury expression and clinicopathological factors were also investigated. In accordance with the previously proposed hypothesis that the expression of Brachyury is positively associated with tumorigenesis and malignancy (16-19), the expression of Brachyury in samples of NSCLC from patients with lymph node metastases was observed to be higher than in tumors from patients without metastases. The positive correlation between Brachyury expression and lung tumor malignancy suggests that Brachyury may be associated with lung tumor progression and makes Brachyury a potential target for lung cancer therapy.

Brachyury has widely been reported to function in the initiation and promotion of EMT (16,20). In the current study, the data obtained was consistent with that from previous studies, and suggested that in NSCLC, EMT was associated with the expression of Brachyury. E-cadherin, a cell-adhesion molecule, is a well-known suppressor of cell invasion (3,21). In lung cancer tissues with positive expression of Brachyury, the downregulation of E-cadherin may result in the initiation of EMT.

A clinical trial of a vaccine for Brachyury-positive tumors is currently underway in patients with solid tumours, as a result of further evidence supporting the hypothesis that Brachyury may be an important potential target for tumor therapy (22). In the current study, the data demonstrated that knockdown of Brachyury by specific siRNAs significantly attenuates the resistance of A549 cells to DDP treatment. Kobayashi et al (17) demonstrated that knockdown of Brachyury increases the sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vivo; therefore, Brachyury may be involved in the regulation of cell cycle progression, which alters the therapeutic effects of conventional cancer treatments, including chemotherapy, radiotherapy and immune therapy. Further investigation of Brachyury is required to provide more evidence for its function in cancer therapy.

In conclusion, the present study demonstrated that Brachyury expression was associated with TNM staging, lymph node metastasis and the prognosis of NSCLC. Brachyury expression is also accompanied by the downregulation of E-cadherin and the upregulation of N-cadherin. Brachyury may promote lung cancer via the induction of EMT, which leads to invasion and metastasis of NSCLC, and a consequent poor prognosis. These results, in combination with those of previous studies, support the hypothesis that Brachyury may be a novel target for the prevention and treatment of lung cancer.

**Acknowledgements**

This study was supported by the Liaoning BaiQianWan Talents Program (grant no. 2012921017).
References

1. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746, 2003.

2. Radisky DC: Epithelial-mesenchymal transition. J Cell Sci 118: 4325-4326, 2005.

3. Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39: 305-318, 2007.

4. Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.

5. Herrmann BG, Labeit S, Poustka A, King TR and Lehrach H: Cloning of the T gene required in mesoderm formation in the mouse. Nature 343: 617-622, 1990.

6. Kispert A and Herrmann BG: The Brachyury gene encodes a novel DNA binding protein. EMBO J 12: 4898-4899, 1993.

7. Edwards YH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA and Sowden J: The human homolog T of the mouse T(Brachyury) gene; gene structure, cDNA sequence, and assignment to chromosome 6q27. Genome Res 6: 226-233, 1996.

8. Papaioannou VE and Silver LM: The T-box gene family. Bioessays 20: 9-19, 1998.

9. Technau U and Scholz CB: Origin and evolution of endoderm and mesoderm. Int J Dev Biol 47: 531-539, 2003.

10. Kispert A, Herrmann BG, Leptin M and Reuter R: Homologs of the mouse Brachyury gene are involved in the specification of posterior terminal structures in Drosophila, Tribolium, and Locusta. Genes Dev 8: 2137-2150, 1994.

11. Behr R, Heneweer C, Viebahn C, Denker HW and Thie M: Epithelial-mesenchymal transition in colonies of rhesus monkey embryonic stem cells: A model for processes involved in gastrulation. Stem cells 23: 805-816, 2005.

12. Vidricaire G, Jardine K and McBurney MW: Expression of the Brachyury gene during mesoderm development in differentiating embryonal carcinoma cell cultures. Development 120: 115-122, 1994.

13. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP and Schlömer J: The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13: 2471-2478, 2007.

14. Goldstraw P: Updated staging system for lung cancer. Surg Oncol Clin N Am 20: 655-666, 2011.

15. D’Antonio C, Milano A, Righini R, et al: Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. Anticancer Res 34: 5241-5250, 2014.

16. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J and Palena C: The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 120: 533-544, 2010.

17. Kobayashi Y, Sugiyama T, Imaiyo I, Shimoda M, Ishii K, Akimoto N, Yoshihama N and Mori Y: Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: Implications for a new therapeutic principle. Int J Oncol 44: 1107-1117, 2014.

18. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, Takenoyama M and Maehara Y: Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. Ann Surg Oncol 20 (Suppl 3): S509-S516, 2013.

19. Kilic N, Feldhaus S, Kilic E, et al: Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 47: 1080-1085, 2011.

20. Imaiyo I, Sugiyama T, Kobayashi Y, et al: T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol 41: 1985-1995, 2012.

21. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654, 2008.

22. Hamilton DH, Litzinger MT, Jales A, et al: Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget 4: 1777-1790, 2013.